Emerging Epigenetic Therapies for Brain Tumors

被引:0
|
作者
Lokesh Kukreja
Catherine J. Li
Sathyapriya Ezhilan
Vishwanath R. Iyer
John S. Kuo
机构
[1] The University of Texas at Austin,Department of Neurosurgery, Dell Medical School
[2] The University of Texas,Department of Molecular Biosciences, LIVESTRONG Cancer Institutes and Department of Oncology, Dell Medical School
[3] The University of Texas at Austin,Department of Neurosurgery, Mulva Clinic for the Neurosciences and LIVESTRONG Cancer Institutes and Department of Oncology, Dell Medical School
[4] China Medical University,Graduate Institute of Biomedical Sciences
来源
NeuroMolecular Medicine | 2022年 / 24卷
关键词
Brain tumors; Epigenetic; Mechanisms; Clinical trials;
D O I
暂无
中图分类号
学科分类号
摘要
Malignant brain tumors are among the most intractable cancers, including malignancies such as glioblastoma, diffuse midline glioma, medulloblastoma, and ependymoma. Unfortunately, treatment options for these brain tumors have been inadequate and complex, leading to poor prognoses and creating a need for new treatment modalities. Aberrant epigenetics define these types of tumors, with underlying changes in DNA methylation, histone modifications, chromatin structure and noncoding RNAs. Epigenetic-targeted therapies are an alternative that have the potential to reverse the epigenetic deregulation underpinning brain malignancies. Various drugs targeting epigenetic regulators have shown promise in preclinical and clinical testing. In this review, we highlight some of the recent emerging epigenetic targeted therapies for brain tumors being evaluated in the discovery phase and in clinical trials.
引用
收藏
页码:41 / 49
页数:8
相关论文
共 50 条
  • [1] Emerging Epigenetic Therapies for Brain Tumors
    Kukreja, Lokesh
    Li, Catherine J.
    Ezhilan, Sathyapriya
    Iyer, Vishwanath R.
    Kuo, John S.
    NEUROMOLECULAR MEDICINE, 2022, 24 (01) : 41 - 49
  • [2] Emerging molecular therapies for brain tumors
    Van Meir, EG
    Bellail, A
    Phuphanich, S
    SEMINARS IN ONCOLOGY, 2004, 31 (02) : 38 - 46
  • [3] Epigenetic Reprogramming and Emerging Epigenetic Therapies in CML
    Bugler, Jane
    Kinstrie, Ross
    Scott, Mary T.
    Vetrie, David
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2019, 7
  • [4] Epigenetic modification in chromatin machinery and its deregulation in pediatric brain tumors: Insight into epigenetic therapies
    Maury, Eleonore
    Hashizume, Rintaro
    EPIGENETICS, 2017, 12 (05) : 353 - 369
  • [5] Modelling Resistance to Emerging Epigenetic Therapies
    Fong, Chun Yew
    Gilan, Omer
    Lam, Enid
    Rubin, Alan
    Morison, Jessica
    Giotopoulos, George
    Stanley, Kym
    Sarah, Ftouni
    Tyler, Dean
    Lugo, Dave
    Jeffrey, Philip
    Gregory, Richard
    Schreuder, Jaring
    Naik, Shalin
    Kouzarides, Tony
    Huntly, Brian
    Johnstone, Ricky W.
    Prinjha, Rab K.
    Papenfuss, Anthony
    Dawson, Mark A.
    BLOOD, 2014, 124 (21)
  • [6] Emerging strategies for delivering antiangiogenic therapies to primary and metastatic brain tumors
    Askoxylakis, Vasileios
    Arvanitis, Costas D.
    Wong, Christina S. F.
    Ferraro, Gino B.
    Jain, Rakesh K.
    ADVANCED DRUG DELIVERY REVIEWS, 2017, 119 : 159 - 174
  • [8] EMERGING THERAPIES FOR ORPHAN TUMORS: NEUROENDOCRINE TUMORS
    Van Cutsem, E.
    Verslype, C.
    ANNALS OF ONCOLOGY, 2008, 19 : 35 - 35
  • [9] Emerging epigenetic-modulating therapies in lymphoma
    David Sermer
    Laura Pasqualucci
    Hans-Guido Wendel
    Ari Melnick
    Anas Younes
    Nature Reviews Clinical Oncology, 2019, 16 : 494 - 507
  • [10] Emerging epigenetic-modulating therapies in lymphoma
    Sermer, David
    Pasqualucci, Laura
    Wendel, Hans-Guido
    Melnick, Ari
    Younes, Anas
    NATURE REVIEWS CLINICAL ONCOLOGY, 2019, 16 (08) : 494 - 507